Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

By R. Sylvester, A. van der Meijden, D. Lamm. Journal of Urology, 2002

1,247 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e560b8974433848cb21705fd999b5212e91c6d9d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Surgery

Citations in the corpus

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. (2009, background): “BCG but not intravesical chemotherapy additionally reduces the risk of progression in high-risk NMIBC patients [93–96].”
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. (2009, background): “Moreover, BCG immunotherapy markedly improves the outcome of high risk nonmuscle invasive bladder cancer.(2) Nevertheless, a subgroup of patients fails to respond and is at risk for disease progression.”
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. (2013, methodology): “For optimal efficacy, BCG must be given on a maintenance schedule [76,80, 84,85] (LE: 1a).”
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021, methodology): “For optimal efficacy, the induction course must be followed by maintenance instillations [105,109,113,114] (LE: 1a).”
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (2017, methodology): “The size of the reduction was similar in patients with TaT1 papillary tumours, and in those with CIS [91].”
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, methodology): “BCG intravesical treatment is associated with more side effects than intravesical chemotherapy [101] (LE: 1a).”